VMT02 not checked

Perspective Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Diagnostic imaging radiopharmaceutical; by intravenous infusion”In the company’s words, NCT04904120 on ClinicalTrials.gov
Tested for
Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal
Main trialPhase 1
“The study hypothesis is that new imaging agents \[203Pb\]VMT01 and \[68Ga\]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.”In the company’s words, NCT04904120 on ClinicalTrials.gov

Other drugs for Melanoma (Skin)

All 195 drugs for Melanoma (Skin)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 20 Sep 2022 Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow VMT02

Following is part of Solo: you see every change to VMT02 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in